These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25173701)

  • 1. Stabilization of protein-protein interactions by small molecules.
    Giordanetto F; Schäfer A; Ottmann C
    Drug Discov Today; 2014 Nov; 19(11):1812-1821. PubMed ID: 25173701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of protein-protein interactions in drug discovery.
    Andrei SA; Sijbesma E; Hann M; Davis J; O'Mahony G; Perry MWD; Karawajczyk A; Eickhoff J; Brunsveld L; Doveston RG; Milroy LG; Ottmann C
    Expert Opin Drug Discov; 2017 Sep; 12(9):925-940. PubMed ID: 28695752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of Protein-Protein Interactions in chemical biology and drug discovery.
    Bier D; Thiel P; Briels J; Ottmann C
    Prog Biophys Mol Biol; 2015 Oct; 119(1):10-9. PubMed ID: 26093250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Compound Classes: Protein-Protein Interactions.
    Ottmann C
    Handb Exp Pharmacol; 2016; 232():125-38. PubMed ID: 26489828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of Rigidity in Designing Small Molecule Drugs To Tackle Protein-Protein Interactions (PPIs) through Stabilization of Desired Conformers.
    Lawson ADG; MacCoss M; Heer JP
    J Med Chem; 2018 May; 61(10):4283-4289. PubMed ID: 29140691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule modulation of p53 protein-protein interactions.
    Kuusk A; Boyd H; Chen H; Ottmann C
    Biol Chem; 2020 Jul; 401(8):921-931. PubMed ID: 32049643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data.
    Sugaya N; Ikeda K; Tashiro T; Takeda S; Otomo J; Ishida Y; Shiratori A; Toyoda A; Noguchi H; Takeda T; Kuhara S; Sakaki Y; Iwayanagi T
    BMC Pharmacol; 2007 Aug; 7():10. PubMed ID: 17705877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulators of 14-3-3 Protein-Protein Interactions.
    Stevers LM; Sijbesma E; Botta M; MacKintosh C; Obsil T; Landrieu I; Cau Y; Wilson AJ; Karawajczyk A; Eickhoff J; Davis J; Hann M; O'Mahony G; Doveston RG; Brunsveld L; Ottmann C
    J Med Chem; 2018 May; 61(9):3755-3778. PubMed ID: 28968506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study.
    Milroy LG; Brunsveld L; Ottmann C
    ACS Chem Biol; 2013 Jan; 8(1):27-35. PubMed ID: 23210482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An optimised small-molecule stabiliser of the 14-3-3-PMA2 protein-protein interaction.
    Richter A; Rose R; Hedberg C; Waldmann H; Ottmann C
    Chemistry; 2012 May; 18(21):6520-7. PubMed ID: 22467351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?
    Thiel P; Kaiser M; Ottmann C
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2012-8. PubMed ID: 22308055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interfering peptides targeting protein-protein interactions: the next generation of drugs?
    Bruzzoni-Giovanelli H; Alezra V; Wolff N; Dong CZ; Tuffery P; Rebollo A
    Drug Discov Today; 2018 Feb; 23(2):272-285. PubMed ID: 29097277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting druggable binding sites at the protein-protein interface.
    Fuller JC; Burgoyne NJ; Jackson RM
    Drug Discov Today; 2009 Feb; 14(3-4):155-61. PubMed ID: 19041415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wrapping mimicking in drug-like small molecules disruptive of protein-protein interfaces.
    Accordino SR; Morini MA; Sierra MB; Fris JA; Appignanesi GA; Fernández A
    Proteins; 2012 Jul; 80(7):1755-65. PubMed ID: 22422633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Druggable protein-protein interactions--from hot spots to hot segments.
    London N; Raveh B; Schueler-Furman O
    Curr Opin Chem Biol; 2013 Dec; 17(6):952-9. PubMed ID: 24183815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target identification of covalently binding drugs by activity-based protein profiling (ABPP).
    Pichler CM; Krysiak J; Breinbauer R
    Bioorg Med Chem; 2016 Aug; 24(15):3291-303. PubMed ID: 27085673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Project ranks billions of drug interactions.
    Reardon S
    Nature; 2013 Nov; 503(7477):449-50. PubMed ID: 24284710
    [No Abstract]   [Full Text] [Related]  

  • 18. Exploring the relationship between hub proteins and drug targets based on GO and intrinsic disorder.
    Fu Y; Guo Y; Wang Y; Luo J; Pu X; Li M; Zhang Z
    Comput Biol Chem; 2015 Jun; 56():41-8. PubMed ID: 25854804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface.
    Bier D; Bartel M; Sies K; Halbach S; Higuchi Y; Haranosono Y; Brummer T; Kato N; Ottmann C
    ChemMedChem; 2016 Apr; 11(8):911-8. PubMed ID: 26644359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.
    Singh SS; Jois SD
    Adv Protein Chem Struct Biol; 2018; 111():1-59. PubMed ID: 29459028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.